Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Status:
Completed
Trial end date:
2016-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of ascending intravenous
(IV) and subcutaneous (SC) doses of MEDI-551 in adult subjects with relapsing forms of
multiple sclerosis (MS).